Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses

Antiviral Research

Volumn 98, Issue 3, 2013, Pages 432-440

  Chang, Jinhong ^a   Warren, Travis K ^b   Zhao, Xuesen ^a   Gill, Tina ^a   Guo, Fang ^a   Wang, Lijuan ^a   Comunale, Mary Ann ^a   Du, Yanming ^c   Alonzi, Dominic S ^d   Yu, Wenquan ^c   Ye, Hong ^c   Liu, Fei ^a   Guo, Ju Tao ^a   Mehta, Anand ^a   Cuconati, Andrea ^c   Butters, Terry D ^d   Bavari, Sina ^b   Xu, Xiaodong ^c,e   Block, Timothy M ^a,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c BARUCH S BLUMBERG INSTITUTE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Enantigen Therapeutics Incorporated   (United States)

Author keywords

Ebola virus; ER glucosidase; Hemorrhagic fever virus; Imino sugar; Marburg virus

Indexed keywords

ALPHA GLUCOSIDASE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CM 10 18; IHVR 11029; IHVR 17028; IHVR 19029; IMINOSUGAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; HEMORRHAGIC FEVER; IC 50; MALE; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS VIRULENCE;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIVIRAL AGENTS; DENGUE; DOGS; DRUG EVALUATION, PRECLINICAL; EBOLAVIRUS; ENDOPLASMIC RETICULUM; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMINO SUGARS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, INBRED BALB C; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

DENGUE VIRUS; EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MUS;

EID: 84877100308     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.03.023     Document Type: Article

References (45)

1. Alonzi D.S., Neville D.C., Lachmann R.H., Dwek R.A., Butters T.D. Glucosylated free oligosaccharides are biomarkers of endoplasmic-reticulum alpha-glucosidase inhibition. Biochem. J. 2008, 409(2):571-580.
2. Ambrosio A., Saavedra M., Mariani M., Gamboa G., Maiza A. Argentine hemorrhagic fever vaccines. Hum. Vaccin. 2011, 7(6):694-700.
3. Block T.M., Jordan R. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antiviral Chem. Chemother. 2001, 12(6):317-325.
4. Block T.M., Lu X., Platt F.M., Foster G.R., Gerlich W.H., Blumberg B.S., Dwek R.A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA 1994, 91(6):2235-2239.
5. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 2007, 11(4):685-706.
6. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287(18):2391-2405.
7. Bray M. Pathogenesis of viral hemorrhagic fever. Curr. Opin. Immunol. 2005, 17(4):399-403.
8. Bridges C.G., Ahmed S.P., Kang M.S., Nash R.J., Porter E.A., Tyms A.S. The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection. Glycobiology 1995, 5(2):249-253.
9. Chang J., Wang L., Ma D., Qu X., Guo H., Xu X., Mason P.M., Bourne N., Moriarty R., Gu B., Guo J.T., Block T.M. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 2009, 53(4):1501-1508.
10. Chang J., Schul W., Butters T.D., Yip A., Liu B., Goh A., Lakshminarayana S.B., Alonzi D., Reinkensmeier G., Pan X., Qu X., Weidner J.M., Wang L., Yu W., Borune N., Kinch M.A., Rayahin J.E., Moriarty R., Xu X., Shi P.Y., Guo J.T., Block T.M. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011, 89(1):26-34.
11. Chang J., Schul W., Yip A., Xu X., Guo J.T., Block T.M. Competitive inhibitor of cellular alpha-glucosidases protects mice from lethal dengue virus infection. Antiviral Res. 2011, 92(2):369-371.
12. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206(2):935-944.
13. Cote M., Misasi J., Ren T., Bruchez A., Lee K., Filone C.M., Hensley L., Li Q., Ory D., Chandran K., Cunningham J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011, 477(7364):344-348.
14. Datema R., Romero P.A., Rott R., Schwarz R.T. On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus. Arch. Virol. 1984, 81(1-2):25-39.
15. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Invest. Drugs 2009, 10(8):860-870.
16. Dwek R.A., Butters T.D., Platt F.M., Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 2002, 1(1):65-75.
17. EMEA (2003). Scientific Discussion - Zavesca.
18. Geffen N. Beyond HAART: scientists and activists need to work together. Lancet 2009, 374(9693):860-861.
19. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 2004, 10(Suppl. 12):S110-S121.
20. Gu B., Mason P., Wang L., Norton P., Bourne N., Moriarty R., Mehta A., Despande M., Shah R., Block T. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antiviral Chem. Chemother. 2007, 18(1):49-59.
21. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 1995, 69(11):6705-6711.
22. Helenius A., Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Ann. Rev. Biochem. 2004, 73:1019-1049.
23. Huggins J., Zhang Z.X., Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis. 1999, 179(Suppl. 1):S240-S247.
24. Jordan R., Nikolaeva O.V., Wang L., Conyers B., Mehta A., Dwek R.A., Block T.M. Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions. Virology 2002, 295(1):10-19.
25. Karlsson G.B., Butters T.D., Dwek R.A., Platt F.M. Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J. Biol. Chem. 1993, 268(1):570-576.
26. Kortepeter M.G., Bausch D.G., Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 2011, 204(Suppl. 3):S810-S816.
27. LeDuc J.W. Epidemiology of hemorrhagic fever viruses. Rev. Infect. Dis. 1989, 11(Suppl. 4):S730-S735.
28. Mahanty S., Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 2004, 4(8):487-498.
29. Malvoisin E., Wild F. The role of N-glycosylation in cell fusion induced by a vaccinia recombinant virus expressing both measles virus glycoproteins. Virology 1994, 200(1):11-20.
30. Mellor H.R., Neville D.C., Harvey D.J., Platt F.M., Dwek R.A., Butters T.D. Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem. J. 2004, 381(Pt 3):867-875.
31. Qu X., Pan X., Weidner J., Yu W., Alonzi D., Xu X., Butters T., Block T., Guo J.T., Chang J. Inhibitors of Endoplasmic Reticulum {alpha}-Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release. Antimicrob. Agents Chemother. 2011, 55(3):1036-1044.
32. Radoshitzky S.R., Warfield K.L., Chi X., Dong L., Kota K., Bradfute S.B., Gearhart J.D., Retterer C., Kranzusch P.J., Misasi J.N., Hogenbirk M.A., Wahl-Jensen V., Volchkov V.E., Cunningham J.M., Jahrling P.B., Aman M.J., Bavari S., Farzan M., Kuhn J.H. Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. J. Virol. 2011, 85(17):8502-8513.
33. Rathore A.P., Paradkar P.N., Watanabe S., Tan K.H., Sung C., Connolly J.E., Low J., Ooi E.E., Vasudevan S.G. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011, 92(3):453-460.
34. Reuser A.J., Wisselaar H.A. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur. J. Clin. Invest. 1994, 24(Suppl. 3):19-24.
35. Schul W., Liu W., Xu H.Y., Flamand M., Vasudevan S.G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 2007, 195(5):665-674.
36. Sessions O.M., Barrows N.J., Souza-Neto J.A., Robinson T.J., Hershey C.L., Rodgers M.A., Ramirez J.L., Dimopoulos G., Yang P.L., Pearson J.L., Garcia-Blanco M.A. Discovery of insect and human dengue virus host factors. Nature 2009, 458(7241):1047-1050.
37. Steinmann E., Whitfield T., Kallis S., Dwek R.A., Zitzmann N., Pietschmann T., Bartenschlager R. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007, 46(2):330-338.
38. Taylor D.L., Sunkara P.S., Liu P.S., Kang M.S., Bowlin T.L., Tyms A.S. 6-0-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs. AIDS 1991, 5(6):693-698.
39. Towner J.S., Sealy T.K., Khristova M.L., Albarino C.G., Conlan S., Reeder S.A., Quan P.L., Lipkin W.I., Downing R., Tappero J.W., Okware S., Lutwama J., Bakamutumaho B., Kayiwa J., Comer J.A., Rollin P.E., Ksiazek T.G., Nichol S.T. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008, 4(11):e1000212.
40. Warren T.K., Warfield K.L., Wells J., Enterlein S., Smith M., Ruthel G., Yunus A.S., Kinch M.S., Goldblatt M., Aman M.J., Bavari S. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents Chemother. 2010, 54(5):2152-2159.
41. Warren T.K., Warfield K.L., Wells J., Swenson D.L., Donner K.S., Van Tongeren S.A., Garza N.L., Dong L., Mourich D.V., Crumley S., Nichols D.K., Iversen P.L., Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010, 16(9):991-994.
42. Watanabe S., Rathore A.P., Sung C., Lu F., Khoo Y.M., Connolly J., Low J., Ooi E.E., Lee H.S., Vasudevan S.G. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012, 96(1):32-35.
43. Wu S.F., Lee C.J., Liao C.L., Dwek R.A., Zitzmann N., Lin Y.L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 2002, 76(8):3596-3604.
44. Yu W., Gill T., Wang L., Du Y., Ye H., Qu X., Guo J.T., Cuconati A., Zhao K., Block T.M., Xu X., Chang J. Design, synthesis, and biological evaluation of N-Alkylated Deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. J. Med. Chem. 2012, 55(13):6061-6075.
45. Zitzmann N., Mehta A.S., Carrouee S., Butters T.D., Platt F.M., McCauley J., Blumberg B.S., Dwek R.A., Block T.M. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. USA 1999, 96(21):11878-11882.